BRPI0711310B8 - composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo - Google Patents

composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo

Info

Publication number
BRPI0711310B8
BRPI0711310B8 BRPI0711310A BRPI0711310A BRPI0711310B8 BR PI0711310 B8 BRPI0711310 B8 BR PI0711310B8 BR PI0711310 A BRPI0711310 A BR PI0711310A BR PI0711310 A BRPI0711310 A BR PI0711310A BR PI0711310 B8 BRPI0711310 B8 BR PI0711310B8
Authority
BR
Brazil
Prior art keywords
map kinase
radical
optionally substituted
formula
pharmaceutical composition
Prior art date
Application number
BRPI0711310A
Other languages
English (en)
Portuguese (pt)
Inventor
Festus Charles Moffat David
Pintat Stephane
John Davies Stephen
Original Assignee
Chroma Therapeutics Ltd
Macrophage Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608855A external-priority patent/GB0608855D0/en
Priority claimed from GB0613914A external-priority patent/GB0613914D0/en
Application filed by Chroma Therapeutics Ltd, Macrophage Pharma Ltd filed Critical Chroma Therapeutics Ltd
Publication of BRPI0711310A2 publication Critical patent/BRPI0711310A2/pt
Publication of BRPI0711310B1 publication Critical patent/BRPI0711310B1/pt
Publication of BRPI0711310B8 publication Critical patent/BRPI0711310B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0711310A 2006-05-04 2007-05-01 composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo BRPI0711310B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0608855A GB0608855D0 (en) 2006-05-04 2006-05-04 Inhibitors of MAP kinase enzymes
GB0608855.3 2006-05-04
GB0613914.1 2006-05-04
GB0613914A GB0613914D0 (en) 2006-07-13 2006-07-13 Inhibitors of p38 map kinase
PCT/GB2007/001596 WO2007129040A1 (en) 2006-05-04 2007-05-01 p38 MAP KINASE INHIBITORS

Publications (3)

Publication Number Publication Date
BRPI0711310A2 BRPI0711310A2 (pt) 2011-12-06
BRPI0711310B1 BRPI0711310B1 (pt) 2020-12-15
BRPI0711310B8 true BRPI0711310B8 (pt) 2021-05-25

Family

ID=38268953

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711310A BRPI0711310B8 (pt) 2006-05-04 2007-05-01 composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo

Country Status (15)

Country Link
US (1) US8044211B2 (enExample)
EP (1) EP2013175B9 (enExample)
JP (1) JP5340918B2 (enExample)
KR (1) KR101429780B1 (enExample)
CN (1) CN102942520B (enExample)
AU (1) AU2007246869B2 (enExample)
BR (1) BRPI0711310B8 (enExample)
CA (1) CA2650970C (enExample)
CY (1) CY1118518T1 (enExample)
DK (1) DK2013175T5 (enExample)
ES (1) ES2605727T3 (enExample)
HU (1) HUE033281T2 (enExample)
NZ (1) NZ573348A (enExample)
PT (1) PT2013175T (enExample)
WO (1) WO2007129040A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
CA2668070A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
UA98961C2 (uk) 2007-06-27 2012-07-10 Астразенека Аб Похідні піразинону та їх застосування у лікуванні легеневих захворювань
WO2009060160A1 (en) * 2007-11-07 2009-05-14 Chroma Therapeutics Ltd. P38 map kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
ES2427892T3 (es) * 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
SI3222616T1 (sl) 2012-10-17 2019-10-30 Macrophage Pharma Ltd N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163957A0 (en) * 2002-03-14 2005-12-18 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
MX2007013257A (es) * 2005-05-05 2008-01-21 Chroma Therapeutics Ltd Conjugados de ester de alfa-aminoacido-farmaco hidrolizables por carboxilesterasa.
ES2427892T3 (es) * 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38

Also Published As

Publication number Publication date
CA2650970A1 (en) 2007-11-15
WO2007129040A1 (en) 2007-11-15
BRPI0711310A2 (pt) 2011-12-06
EP2013175B9 (en) 2020-11-11
CY1118518T1 (el) 2017-07-12
NZ573348A (en) 2012-01-12
ES2605727T9 (es) 2020-12-11
DK2013175T5 (da) 2020-12-21
AU2007246869A1 (en) 2007-11-15
HUE033281T2 (en) 2017-11-28
US8044211B2 (en) 2011-10-25
AU2007246869B2 (en) 2012-10-18
EP2013175B1 (en) 2016-11-09
PT2013175T (pt) 2017-02-14
CA2650970C (en) 2014-09-16
KR101429780B1 (ko) 2014-08-18
KR20090014187A (ko) 2009-02-06
US20090099185A1 (en) 2009-04-16
ES2605727T3 (es) 2017-03-16
CN102942520A (zh) 2013-02-27
EP2013175A1 (en) 2009-01-14
JP5340918B2 (ja) 2013-11-13
DK2013175T3 (en) 2017-02-20
JP2009535385A (ja) 2009-10-01
CN102942520B (zh) 2015-03-04
BRPI0711310B1 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
ZA202007843B (en) Tertiary amine substituted coumarin compounds and their uses as fluorescent labels
CY1118518T1 (el) Αναστολεις της κινασης p38 μαp
ECSP055910A (es) Nuevos acidos carboxilicos y sus esteres, medicamentos que contienen estos compuestos y procedimientos para su preparacion
AR082109A1 (es) Derivados de bipiridilo
PE20081135A1 (es) Derivados que contienen sulfamoilo y sus usos
BR112017005767A2 (pt) composições de limpeza contendo uma polieteramina
PE20151764A1 (es) Derivados de pirrolo[2,3-d]pirimidina
EA201100189A1 (ru) Гетероарильные производные в качестве ингибиторов dgat1
EA201190099A1 (ru) (1-фенил-2-пиридин-4-ил)этиловые эфиры бензойной кислоты в качестве ингибиторов фосфодиэстеразы
ATE484504T1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
BR112014009102A2 (pt) compostos químicos
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
PE20140970A1 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a
EA201100944A1 (ru) Производные изоксазола, предназначенные для применения в качестве регуляторов роста растений
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
CY1111269T1 (el) Ρυθμιστες βενζιμιδαζολης του vr1
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
UY30104A1 (es) Derivados nuevos de urea ciclica, su preparacinn y su utilizacinn farmacéutica como inhibidores de cinasas
UA122966C2 (uk) Композиції з покращеним ефектом інгібування уреази, які містять триамід (тіо)фосфорної кислоти і додаткові сполуки, такі як аміни і барвники
ECSP056232A (es) Nuevos compuestos
MX2010003849A (es) Antagonistas de cgrp.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MACROPHAGE PHARMA LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2721 DE 28-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.